{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-100755","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.818444+00:00","generated_at":"2026-06-29T21:42:57.330146+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Natera Q2 revenue up 64% to $142M; guides FY2021 revenue to $600-620M","bullets":["Product revenue $137.2M, +70.7% YoY; processed 375,700 tests, +60.5%.","Net loss $116.0M ($1.32/share) vs $59.6M ($0.75) a year ago.","Raised 2021 revenue guidance to $600-620M from $550-575M (second increase).","Completed $551.2M net follow-on equity offering in July 2021.","CMS awarded ADLT status for Signatera MRD test; GSK phase III trial announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-100755","json":"https://secwatch.observer/filing/0001104659-21-100755.json","markdown":"https://secwatch.observer/filing/0001104659-21-100755.md","text":"https://secwatch.observer/filing/0001104659-21-100755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465921100755/0001104659-21-100755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465921100755/tm2124237d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T21:42:57.330146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}